surmount-1 tirzepatide obesity nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Three-year study of tirzepatide shows

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial - Springer Nature Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide - The Journal of Clinical Endocrinology & Metabolism Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - JCI Insight Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations

Discuss with your doctor Ultimately, your healthcare provider knows your medical history and goals best

At Klinic, we pride ourselves on removing the barriers that stand between you and better health

In preclinical models , this contributes to increased metabolic activity and reduced fat accumulation

clinicaltrials.gov/study/NCT03811561 27

Potential mechanisms of action related to the efficacy and safety of cladribine